The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMY Detailed Price Forecast - CNN Money||View ALPMY Detailed Summary - Google Finance|
|View ALPMY Detailed Summary - Yahoo! Finance||View ALPMY Stock Research & Analysis - Zacks.com|
|View ALPMY Trends & Analysis - Trade-Ideas||View ALPMY Major Holders - Barrons|
|View ALPMY Call Transcripts - NASDAQ||View ALPMY Breaking News & Analysis - Seeking Alpha|
|View ALPMY Annual Report - CompanySpotlight.com||View ALPMY OTC Short Report - OTCShortReport.com|
|View ALPMY Fundamentals - TradeKing||View ALPMY SEC Filings - Bar Chart|
|View Historical Prices for ALPMY - The WSJ||View Performance/Total Return for ALPMY - Morningstar|
|View the Analyst Estimates for ALPMY - MarketWatch||View the Earnings History for ALPMY - CNBC|
|View the ALPMY Earnings - StockMarketWatch||View ALPMY Buy or Sell Recommendations - MacroAxis|
|View the ALPMY Bullish Patterns - American Bulls||View ALPMY Short Pain Metrics - ShortPainBot.com|
|View ALPMY Stock Mentions - StockTwits||View ALPMY Stock Mentions - PennyStockTweets|
|View ALPMY Stock Mentions - Twitter||View ALPMY Investment Forum News - Investor Hub|
|View ALPMY Stock Mentions - Yahoo! Message Board||View ALPMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMY - SECform4.com||View Insider Transactions for ALPMY - Insider Cow|
|View ALPMY Major Holdings Summary - CNBC||View Insider Disclosure for ALPMY - OTC Markets|
|View Insider Transactions for ALPMY - Yahoo! Finance||View Institutional Holdings for ALPMY - NASDAQ|
|View ALPMY Stock Insight & Charts - FinViz.com||View ALPMY Investment Charts - StockCharts.com|
|View ALPMY Stock Overview & Charts - BarChart||View ALPMY User Generated Charts - Trading View|
TOKYO , Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that XOSPATA ® (generic name: gilteritinib) is now ...
TOKYO , Dec. 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib ...
XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Posted on Wednesday November 28, 2018
- FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs - - XOSPATA is the first and only FLT3 inhibitor approved by the FDA for patients with relapsed or refractory ...
Astellas Pharma gets U.S. nod for blood cancer treatment
Posted on Wednesday November 28, 2018
The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation. The treatment, Xospata, was approved for patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant. The drug, taken once a day in tablet form, will have a wholesale acquisition cost of $22,500 for a month's supply, Astellas said.